(Q34654791)

3 August 2017

title

Inhibition of HSP90 molecular chaperones: moving into the clinic (English)

1 reference

3 August 2017

0 references

Rocío García-Carbonero

object named as

Rocio Garcia-Carbonero

0 references

Amancio Carnero

0 references

Luis Paz-Ares

1 reference

3 August 2017

publication date

1 August 2013

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

e358-69

1 reference

Sick chaperones, cellular stress, and disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Inhibitors of the heat shock response: biology and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Hsp90 molecular chaperone inhibitors: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Targeting HSP90 for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Stable association of hsp90 and p23, but Not hsp70, with active human telomerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Association of NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker histones into nuclei

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Cyclophilin-40: evidence for a dimeric complex with hsp90.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Hop modulates Hsp70/Hsp90 interactions in protein folding

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Hsp90 inhibitors as promising agents for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

High HSP90 expression is associated with decreased survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970169-4

7 January 2021

10.1016/S1470-2045(13)70169-4

Identifiers

DOI

1 reference

3 August 2017

1 reference